|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5 Suppl 1
|
|
pubmed:dateCreated |
2001-2-20
|
|
pubmed:abstractText |
The single oral administration of a mixed endothelin-A-and -B- (ETA/ETB) receptor antagonist, J-104132 (L-753,037) decreased the blood pressure in conscious spontaneously hypertensive rats (SHR), stroke-prone SHR (SHRSP) and Dahl salt-sensitive hypertensive rats fed high-salt diet (DS-H) at doses of 3 and 10 mg/kg, with a duration of approximately 24 h. The magnitude of the antihypertensive effects was greater in DS-H than in SHR and SHRSP Preproendothelin-1 mRNA expression in the kidney and aorta was greater (about twofold) in DS-H than that in nonnotensive Dahl salt-resistant rats fed high-salt diet (DR-H), while there was no difference in preproendothelin-1 mRNA expression between SHR and Wistar Kyoto rats (WKY). An AT1-receptor antagonist, MK-954 (Losartan), also attenuated hypertension in SHR and SHRSP at oral doses of 3 and 10 mg/kg, but bad no effect in DS-H. The concomitant treatment with MK-954 and J-104132 showed additive antihypertensive effects in SHR and SHRSP. In DS-H, MK-954 potentiated the antihypertensive effects of J-104132. From these results, we suggest that: (1) the contribution of endothelin (ET) to the maintenance of hypertension is greater in salt-sensitive hypertensive models than in SHR and SHRSP; (2) the antihypertensive efficacy of ETA/ETB blockade is augmented by AT1-receptor blockade; (3) ET blockers alone or in combination with AT1 antagonists could be useful in the treatment of hypertension for patients who do not respond adequately to renin-angiotensin system inhibitors alone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Endothelin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Endothelins,
http://linkedlifedata.com/resource/pubmed/chemical/J 104132,
http://linkedlifedata.com/resource/pubmed/chemical/Losartan,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Precursors,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Endothelin A,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Endothelin B,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Endothelin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0160-2446
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
S337-41
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11078414-Angiotensin Receptor Antagonists,
pubmed-meshheading:11078414-Animals,
pubmed-meshheading:11078414-Antihypertensive Agents,
pubmed-meshheading:11078414-Blood Pressure,
pubmed-meshheading:11078414-Drug Synergism,
pubmed-meshheading:11078414-Endothelin-1,
pubmed-meshheading:11078414-Endothelins,
pubmed-meshheading:11078414-Losartan,
pubmed-meshheading:11078414-Male,
pubmed-meshheading:11078414-Protein Precursors,
pubmed-meshheading:11078414-Pyridines,
pubmed-meshheading:11078414-RNA, Messenger,
pubmed-meshheading:11078414-Rats,
pubmed-meshheading:11078414-Rats, Inbred SHR,
pubmed-meshheading:11078414-Rats, Inbred WKY,
pubmed-meshheading:11078414-Receptor, Angiotensin, Type 1,
pubmed-meshheading:11078414-Receptor, Angiotensin, Type 2,
pubmed-meshheading:11078414-Receptor, Endothelin A,
pubmed-meshheading:11078414-Receptor, Endothelin B,
pubmed-meshheading:11078414-Receptors, Endothelin
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1 -receptor antagonist, MK-954.
|
|
pubmed:affiliation |
Pharmacology Laboratory, Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan. ikedatk@banyu.co.jp
|
|
pubmed:publicationType |
Journal Article
|
